Covers the 28.3% versus 25.0% weight loss figures, the 12% who quit at 9 mg in TRIUMPH-2, and why online vials sold as Reta aren't the trial drug.
Recap by typeshit. Full story at NCHStats.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A short Philstar Life item on PIONEER 8, a trial of oral semaglutide. The material gives only the title, so tap through for the details.
In an eight-week monkey study, lean mass was 6% of weight lost with the antibody plus semaglutide versus 22% on semaglutide alone. iBio plans human trials in early 2027.
Dr Alo argues semaglutide's bigger story is heart protection, citing SELECT trial results showing fewer cardiovascular events in people without diabetes.
Loading…